Back to News
Market Impact: 0.2
Sandoz Partners With MAbxience On Emicizumab Biosimilar; Pipeline Reaches 40 Assets
Source: Nasdaq
Healthcare & BiotechProduct LaunchesTechnology & Innovation
Sandoz Group announced a collaboration with mAbxience to develop a proposed emicizumab biosimilar. The partnership expands Sandoz's affordable-medicines pipeline and could support its position in biosimilars, though no financial terms, development timeline, or regulatory details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
SDZ0.45
More News
- Google's Gemini becomes latest AI model to break out and hack computer systems
- AI almost led the US military to start a war with China, report says
- Google’s Gemini AI hacks 3 companies in security test, then stops
- Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
- India forces caller-ID apps to feed spam reports to telcos
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal